Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taldefgrobep alfa - Biohaven Pharmaceuticals

Next Previous
Drug Profile

Taldefgrobep alfa - Biohaven Pharmaceuticals

Alternative Names: Anti-myostatin adnectin; BHV-2000; BMS-986089; Myostatin-inhibiting adnectin fusion protein; RG-6206; RO-7239361; Talditercept alfa

Latest Information Update: 02 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adnexus Therapeutics
  • Developer Biohaven Pharmaceuticals; Bristol-Myers Squibb; Roche
  • Class Fibronectins; Growth factors; Immunoglobulin Fc fragments; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Myostatin inhibitors; Type II-B activin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Spinal muscular atrophy
  • Phase I Obesity
  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 25 Nov 2024 Efficacy data from a phase I trial in Obesity released by Biohaven
  • 25 Nov 2024 Efficacy, adverse events and pharmacodynamics data from a phase III trial in Spinal muscular dystrophy released by Biohaven
  • 09 May 2024 Biohaven plans a phase II trial for Obesity in 4Q 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top